Can Acute Myeloid Leukemia (AML) cause gross hematuria in patients?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can AML Cause Gross Hematuria?

Yes, AML can cause gross hematuria, though it is a rare presenting feature that typically results from thrombocytopenia-related mucosal bleeding and possible occult leukemic infiltration of the urinary tract. 1, 2

Mechanism and Clinical Presentation

Hematuria in AML occurs through two primary mechanisms:

  • Thrombocytopenia-induced bleeding: AML typically presents with bone marrow failure leading to thrombocytopenia, which manifests as bleeding symptoms including petechiae, bruising, and mucosal bleeding. 1 While mucosal bleeding usually presents as gum bleeding or epistaxis, it can occur in any mucosal surface of the body, including the urinary tract. 2

  • Occult leukemic infiltration: Case reports document that gross hematuria can occur without demonstrable leukemic infiltration on imaging studies, suggesting microscopic infiltration of the urinary system that becomes clinically apparent when combined with thrombocytopenia. 2 The hematuria typically subsides after initiating chemotherapy, supporting this mechanism. 2

Coagulopathy Considerations

AML is frequently complicated by coagulation abnormalities that can exacerbate bleeding:

  • Disseminated intravascular coagulation (DIC) occurs in 8.5-25% of non-APL AML cases, with bleeding being a potential manifestation. 3 The prevalence of severe coagulation abnormalities in acute myeloid leukemia across all FAB types is approximately 12%. 4

  • Standard coagulation screening should be performed before any invasive procedures, including evaluation of prothrombin time, partial thromboplastin time, and fibrinogen activity. 5 This is particularly important given that coagulopathy is common at presentation in many leukemias. 5

Clinical Significance and Management

When hematuria is the presenting feature:

  • Maintain high clinical suspicion: While rare as an isolated or main presenting feature, hematuria should be remembered as a possible manifestation of acute leukemia. 2 The diagnosis requires comprehensive evaluation including complete blood count with differential and bone marrow examination. 5, 1

  • Immediate supportive care: Thrombocytopenia-related symptoms require platelet transfusion support, with thresholds of ≥50,000/μL if clinical coagulopathy or overt bleeding is present. 6 For non-APL AML with DIC, maintain fibrinogen >150 mg/dL with cryoprecipitate and fresh frozen plasma. 6

  • Definitive treatment: The hematuria typically resolves with initiation of appropriate chemotherapy for the underlying leukemia, as the cytoreduction addresses both the thrombocytopenia and any occult infiltration. 2

Important Caveats

The absence of demonstrable urinary tract infiltration on imaging does not exclude AML as the cause of hematuria when other hematologic abnormalities are present. 2 The combination of gross hematuria with cytopenias or other systemic symptoms warrants immediate hematologic evaluation rather than isolated urologic workup.

References

Guideline

Acute Myeloid Leukemia Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Frank hematuria as the presentation feature of acute leukemia.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2010

Research

[Blood coagulation disorders in leukemia].

Wiener medizinische Wochenschrift (1946), 1991

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Disseminated Intravascular Coagulation in Non-APL Acute Myeloid Leukemia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.